Cargando…

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future

Objectives: The aim of this study is to conduct an analysis on the regulation and application of managed entry agreements (MEA) for oncology drugs across different European countries. Methods: Literature search and document analysis were performed between September 2015 and June 2016 to collect info...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pauwels, Kim, Huys, Isabelle, Vogler, Sabine, Casteels, Minne, Simoens, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378787/ https://www.ncbi.nlm.nih.gov/pubmed/28420990 http://dx.doi.org/10.3389/fphar.2017.00171

Ejemplares similares

Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs
por: Pauwels, Kim, et al.
Publicado: (2016)

Toward a European definition for a drug shortage: a qualitative study
por: De Weerdt, Elfi, et al.
Publicado: (2015)

Insights into European Drug Shortages: A Survey of Hospital Pharmacists
por: Pauwels, Kim, et al.
Publicado: (2015)

Drug shortages in European countries: a trade-off between market attractiveness and cost containment?
por: Pauwels, Kim, et al.
Publicado: (2014)

Time Investment in Drug Supply Problems by Flemish Community Pharmacies
por: De Weerdt, Elfi, et al.
Publicado: (2017)

Financial based agreements and performance based agreements: the Belgian experience
por: Pauwels, Kim, et al.
Publicado: (2015)

Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012
por: Pauwels, Kim, et al.
Publicado: (2017)

What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population
por: Pauwels, Kim, et al.
Publicado: (2019)

How to Value Orphan Drugs? A Review of European Value Assessment Frameworks
por: Blonda, Alessandra, et al.
Publicado: (2021)

Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory study
por: De Weerdt, Elfi, et al.
Publicado: (2017)

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
por: Barcina Lacosta, Teresa, et al.
Publicado: (2022)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
por: Car, Elif, et al.
Publicado: (2023)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
por: Abdallah, Khadidja, et al.
Publicado: (2021)

Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022)

Call for a Dedicated European Legal Framework for Bacteriophage Therapy
por: Verbeken, Gilbert, et al.
Publicado: (2014)

Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies
por: Michelsen, Sissel, et al.
Publicado: (2020)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022)

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
por: Kanters, Tim A., et al.
Publicado: (2017)

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
por: Vandenplas, Yannick, et al.
Publicado: (2021)

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
por: Vandenplas, Yannick, et al.
Publicado: (2021)

Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe
por: Bouvy, Jacoline C., et al.
Publicado: (2018)

Introduction of managed entry agreements in Korea: Problem, policy, and politics
por: Kim, Hyungmin, et al.
Publicado: (2023)

The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape
por: Moorkens, Evelien, et al.
Publicado: (2017)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022)

Sharing of Clinical Trial Data and Samples: The Cancer Patient Perspective
por: Broes, Stefanie, et al.
Publicado: (2020)

Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making
por: Saesen, Robbe, et al.
Publicado: (2020)

Valorising and Creating Access to Innovative Medicines in the European Union
por: Annemans, Lieven, et al.
Publicado: (2011)

The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy
por: Xoxi, Entela, et al.
Publicado: (2021)

European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
por: Barbier, Liese, et al.
Publicado: (2020)

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
por: Dutta, Binita, et al.
Publicado: (2019)

European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice
por: Barbier, Liese, et al.
Publicado: (2020)

Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure
por: Vogler, Sabine, et al.
Publicado: (2021)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
por: Morel, Thomas, et al.
Publicado: (2013)

Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?
por: Jommi, Claudio, et al.
Publicado: (2021)

From basic to advanced computerised intravenous to oral switch for paracetamol and antibiotics: an interrupted time series analysis
por: Quintens, Charlotte, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4p8b5sumu0fhbeprn6s1e4qjp9